The Use of Intravenous Sotalol in Cardiac Arrhythmias

Heart, Lung & Circulation
Rahul SamantaPramesh Kovoor

Abstract

Sotalol is a non-selective beta-adrenergic blocking agent without intrinsic sympathomimetic activity. It has the additional unique property of producing pronounced prolongation of the cardiac action potential duration. Sotalol therapy has been indicated for the management of supraventricular arrhythmias, refractory life threatening ventricular arrhythmias and atrial fibrillation/flutter. Until recently, sotalol was only available in the oral form, however, it was approved for intravenous administration by the US Food & Drug Administration (FDA). The current recommendations are for sotalol 75-150mg to be administered intravenously over 5hours. This rate of administration does not reflect the majority of the research that has been performed with regards to intravenous sotalol. Also, the safety of intravenous bolus dosing of 100mg over 1 and 5minutes has previously been demonstrated. The antiarrhythmic action of sotalol depends on its ability to prolong refractoriness in the nodal and extra nodal tissue. Hence, by giving a lower dose over a long duration, patients may not necessarily benefit from its anti-arrhythmic potential. The purpose of this article is to review the research that has been conducted with regards to dosage and ...Continue Reading

Citations

Apr 25, 2020·JACC. Clinical Electrophysiology·Alejandro A BorquezJames C Perry
Jul 23, 2021·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Daniel A N MascarenhasBharat K Kantharia
Oct 2, 2020·Cardiovascular & Hematological Disorders Drug Targets·Alireza GheiniAli Pooria
Dec 26, 2021·Journal of Cardiovascular Electrophysiology·Daniel L VarelaThomas Jared Bunch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses
C S Dunnington
Current Problems in Cardiology
S K Huang, F I Marcus
Journal of Clinical Pharmacology
A Simon, E Berman
© 2022 Meta ULC. All rights reserved